Author | Tony Rodriguez, MD

Articles

Class effect is good news for men with nonmetastatic CRPC

August 15, 2019

"While much work is still to be done, we have excellent evidence that there is a beneficial class-like effect for the androgen inhibitors enzalutamide, apalutamide, and darolutamide used within the current definition of men with M0 CPRPC," write Michael Cookson, MD, and Tony Rodriguez, MD.